Cramer's 'Mad Money' Recap: Collecting on Debt

Varian on the Vanguard

"I don't want to sound morbid and I don't want to sound offensive, but here could be a lot of money in curing cancer," Cramer said.

That's why he's bullish on Varian Medical Systems(VAR Quote).

Everyone is focusing on drug treatments, but Cramer likes this radiation play.

Usually, the cure is as harmful as the disease, he said, but Varian has a machine that could change that, the Image-Guided Radiation Therapy (IGRT) system.

He said the company was the best of breed in instruments for treating cancer with its SmartBeam Intensity Modulated Radiation Therapy, or IMRT system, even before it started working on the newer IGRT system.

The company may have as much as 70% of the market in the U.S. and perhaps 60% globally, he said, calling it a dominant player on the rise.

As far as growth is concerned, the new system will cost $2 million a machine, vs. $1 million for the old IMRT system.

And IGRT is accessible through Medicare reimbursement effective the first of this year.

Even though Varian CEO Richard M. Levy is retiring in February, the company's long product cycle should trump any bumps that could be caused by a change in management, said Cramer.

An AMR Armistice

In his weekly go-round with senior MarketWatch columnist Herb Greenberg, the two agreed that viewers should stay away from AMR(AMR Quote).

Greenberg said based on AMR's numbers, it's probably going to lose money and furthermore the company has a lot of debt.

While Cramer likes to "pimp stocks all over the world," Greenberg had some words of caution for investors looking to buy on overseas exchanges.

Most importantly, he said, you should only buy companies that you can easily research, which can be difficult with some overseas companies.